Reginald L. Dean

10.2k citations

69 papers · 8.3k indexed · 1 hit paper · h-index 36

Cellular and Molecular Neuroscience top 0.5%
Molecular Biology top 2%
Pharmacology top 0.1%
Cognitive Neuroscience top 0.5%
Physiology top 1%

Co-authors: Raymond T. Bartus Bernard Beer Arnold Lippa Charles Flicker Michael J. Pontecorvo Dwaine F. Emerich Peter J. Elliott J. A. Goas
Topics: Memory and Neural Mechanisms (15 papers)Neurotransmitter Receptor Influence on Behavior (13 papers)Neuroscience and Neuropharmacology Research (13 papers)
Cited by: Cellular and Molecular Neuroscience Pharmacology Neurology
Journals: Science Cancer Research Stroke
Partner nations: United States Ireland Denmark

In The Last Decade

Reginald L. Dean

67 papers receiving 7.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Cholinergic Hypothesis of Geriatric Memory Dysfunction

1982 4.5k citations Raymond T. Bartus, Reginald L. Dean et al. profile →

Peers

Countries citing papers authored by Reginald L. Dean

Since Specialization

Citations

This map shows the geographic impact of Reginald L. Dean's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Reginald L. Dean with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Reginald L. Dean more than expected).

Fields of papers citing papers by Reginald L. Dean

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Reginald L. Dean. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Reginald L. Dean. The network helps show where Reginald L. Dean may publish in the future.

Co-authorship network of co-authors of Reginald L. Dean

This figure shows the co-authorship network connecting the top 25 collaborators of Reginald L. Dean. A scholar is included among the top collaborators of Reginald L. Dean based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Reginald L. Dean. Reginald L. Dean is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The impact of interventions for depression on self-perceptions in young people: A systematic review & meta-analysis 2024 ·Clinical Psychology Review ·Reginald L. Dean,Kathryn J. Lester,E Grant,Andy P. Field,Faith Orchard,Victoria Pile	3
2	Antidepressant-like effects of 3-carboxamido seco-nalmefene (3CS-nalmefene), a novel opioid receptor modulator, in a rat IFN-α-induced depression model 2017 ·Brain Behavior and Immunity ·Charlotte K. Callaghan,(unknown),Reginald L. Dean,Brian I. Knapp,Jean M. Bidlack,Daniel R. Deaver,Shane M. O’Mara	11
3	Effects of oral loperamide on efficacy of naltrexone, baclofen and AM-251 in blocking ethanol self-administration in rats 2011 ·Pharmacology Biochemistry and Behavior ·Reginald L. Dean,(unknown),Mark S. Todtenkopf,Ryan Z. Turncliff,Jean M. Bidlack,Daniel R. Deaver	10
4	PRECLINICAL STUDY: Route of administration affects the ability of naltrexone to reduce amphetamine‐potentiated brain stimulation reward in rats 2009 ·Addiction Biology ·Mark S. Todtenkopf,(unknown),(unknown),Ryan Z. Turncliff,Reginald L. Dean,(unknown),Daniel R. Deaver	17
5	Pharmaceutical treatment for cognitive deficits in Alzheimer’s disease and other neurodegenerative conditions: exploring new territory using traditional tools and established maps 2008 ·Psychopharmacology ·Raymond T. Bartus,Reginald L. Dean	30
6	Vivitrex®, an Injectable, Extended-Release Formulation of Naltrexone, Provides Pharmacokinetic and Pharmacodynamic Evidence of Efficacy for 1 Month in Rats 2003 ·Neuropsychopharmacology ·Raymond T. Bartus,Dwaine F. Emerich,(unknown),(unknown),Reginald L. Dean,(unknown),Anthony S. Basile	56
7	Sustained Release Chemotherapeutic Microspheres Provide Superior Efficacy over Systemic Therapy and Local Bolus Infusions 2002 ·Pharmaceutical Research ·Dwaine F. Emerich,Pamela Snodgrass,(unknown),Reginald L. Dean,(unknown),Joanne Marsh,(unknown),(unknown),Shelley R. Winn,Raymond T. Bartus	38
8	Bradykinin Modulation of Tumor Vasculature: I. Activation of B2 Receptors Increases Delivery of Chemotherapeutic Agents into Solid Peripheral Tumors, Enhancing Their Efficacy 2001 ·Journal of Pharmacology and Experimental Therapeutics ·Dwaine F. Emerich,Pamela Snodgrass,Reginald L. Dean,(unknown),(unknown),(unknown),Hua Xiong,Brant P. Hasler,Joanne Marsh,Melissa Pink,(unknown),Raymond T. Bartus	28
9	The Development of the Bradykinin Agonist Labradimil as a Means to Increase the Permeability of the Blood-Brain Barrier 2001 ·Clinical Pharmacokinetics ·Dwaine F. Emerich,Reginald L. Dean,(unknown),Raymond T. Bartus	90
10	Central Nervous System Diseases 2000 ·Humana Press eBooks ·Dwaine F. Emerich,Reginald L. Dean,Paul R. Sanberg,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown)	48
11	Central nervous system diseases : innovative animal models from lab to clinic 2000 ·Humana Press eBooks ·Dwaine F. Emerich,Reginald L. Dean,Paul R. Sanberg	24
12	Intravenous Cereport (RMP-7) Enhances Delivery of Hydrophilic Chemotherapeutics and Increases Survival in Rats with Metastatic Tumors in the Brain 2000 ·Pharmaceutical Research ·Dwaine F. Emerich,Reginald L. Dean,Joanne Marsh,Melissa Pink,(unknown),Pamela Snodgrass,Raymond T. Bartus	36
13	Cereport® (RMP-7) increases carboplatin levels in brain tumors afterpretreatment with dexamethasone 1999 ·Neuro-Oncology ·Reginald L. Dean,(unknown),Brant P. Hasler,Raymond T. Bartus	22
14	Enhanced delivery of carboplatin into brain tumours with intravenous CereportTM (RMP-7): dramatic differences and insight gained from dosing parameters 1999 ·British Journal of Cancer ·Dwaine F. Emerich,Pamela Snodgrass,Reginald L. Dean,(unknown),Brant P. Hasler,Melissa Pink,Hua Xiong,(unknown),Raymond T. Bartus	48
15	Temporal ordering of pathogenic events following transient global ischemia 1998 ·Brain Research ·Raymond T. Bartus,Reginald L. Dean,Steven Mennerick,David Eveleth,Gary Lynch	48
16	Dissociation of blood-brain barrier permeability and the hypotensive effects of the bradykinin B2 agonist, RMP-7 1996 ·Immunopharmacology ·Peter J. Elliott,Neil J. Hayward,Reginald L. Dean,Raymond T. Bartus	19
17	Pathway across blood-brain barrier opened by the bradykinin agonist, RMP-7 1995 ·Brain Research ·(unknown),Raymond T. Bartus,Phillip M. Friden,Reginald L. Dean,(unknown),Milton Brightman	110
18	Histopathologic Consequences of Moderate Concussion in an Animal Model: Correlations with Duration of Unconsciousness 1994 ·Journal of Neurotrauma ·(unknown),Raymond T. Bartus,Reginald L. Dean,Jill Miotke,Sharon Murphy,(unknown),Harold Goldman	49
19	Tetrahydroaminoacridine, 3,4 diaminopyridine and physostigmine: Direct comparison of effects on memory in aged primates 1988 ·Neurobiology of Aging ·Raymond T. Bartus,Reginald L. Dean	53
20	The Cholinergic Hypothesis: A Historical Overview, Current Perspective, and Future Directions 1985 ·Annals of the New York Academy of Sciences ·Raymond T. Bartus,Reginald L. Dean,Michael J. Pontecorvo,Charles Flicker	326

About Reginald L. Dean

Reginald L. Dean is a scholar working on Cellular and Molecular Neuroscience, Neurology and Biological Psychiatry, having authored 69 papers that have together received 8.3k indexed citations. Recurring topics across this work include Memory and Neural Mechanisms (15 papers), Neurotransmitter Receptor Influence on Behavior (13 papers) and Neuroscience and Neuropharmacology Research (13 papers). The work is most often cited by research in Cellular and Molecular Neuroscience (3.3k citations), Pharmacology (2.9k citations) and Neurology (1.0k citations). Reginald L. Dean has collaborated with scholars based in United States, Ireland and Denmark. Frequent co-authors include Raymond T. Bartus, Bernard Beer, Arnold Lippa, Charles Flicker, Michael J. Pontecorvo, Dwaine F. Emerich, Peter J. Elliott, J. A. Goas, Neil J. Hayward and Stephen K. Fisher. Their work appears in journals such as Science, Cancer Research and Stroke.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact